SV2002000442A - METHOD FOR REGULATING ANGIOGENESIS USING RYK PROTEIN REF. MSB-7266-SV - Google Patents

METHOD FOR REGULATING ANGIOGENESIS USING RYK PROTEIN REF. MSB-7266-SV

Info

Publication number
SV2002000442A
SV2002000442A SV2001000442A SV2001000442A SV2002000442A SV 2002000442 A SV2002000442 A SV 2002000442A SV 2001000442 A SV2001000442 A SV 2001000442A SV 2001000442 A SV2001000442 A SV 2001000442A SV 2002000442 A SV2002000442 A SV 2002000442A
Authority
SV
El Salvador
Prior art keywords
ryk
msb
regulating angiogenesis
association
protein ref
Prior art date
Application number
SV2001000442A
Other languages
Spanish (es)
Inventor
Steve Roczniak
Nathalie A Dubois-Stringfellow
Alya Zolotorev
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of SV2002000442A publication Critical patent/SV2002000442A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE ENCONTRO QUE LA PROTEINA RYK TENIA UNA NOVEDOSA ACTIVIDAD EN LA REGULACION DE LA ANGIOGENESIS. SE CONSTRUYERON NUEVAS PROTEINAS RYK VARIANTES QUE SON VENTAJOSAS PARA MODULAR LA ACTIVIDAD FORMADORA DE CAPILARES DE LAS CELULAS ENDOTELIALES. LAS PROTEINAS RYK VARIANTES PUEDEN SER UTILIZADOS COMO AGENTES TERAPEUTICOS EN ENFERMEDADES TALES COMO EL CANCER, LA CICATRIZACION DE HERIDAS, LAS RETINOPATIAS DIABETICAS, LA DEGENERACION MACULAR Y LAS ENFERMEDADES CARDIOVASCULARES, ASI COMO OTRAS ENFERMEDADES O TRASTORNOS CICLICOS EN LA QUE LA ANGIOGENESIS ESTA INVOLUCRADA EN LA CAUSA O EL TRATAMIENTO DE LA ENFERMEDADI FOUND THAT THE RYK PROTEIN HAD A NEW ACTIVITY IN THE REGULATION OF ANGIOGENESIS. NEW RYK VARIANTS PROTEINS WHICH ARE ADVANTAGE TO MODULATE THE CAPILLARY FORMING ACTIVITY OF ENDOTELIAL CELLS WERE BUILT. RYK VARIANTS PROTEINS CAN BE USED AS THERAPEUTIC AGENTS IN SUCH DISEASES AS CANCER, WOUND HEALING, DIABETIC RETINOPATHICS, MACULAR DEGENERATION AND CARDIOVASTIC ASSOCIATION IN OCCUPATIONAL ASSOCIATION IN OCCUPATIONAL DISEASE CAUSE OR TREATMENT OF THE DISEASE

SV2001000442A 2000-05-10 2001-05-09 METHOD FOR REGULATING ANGIOGENESIS USING RYK PROTEIN REF. MSB-7266-SV SV2002000442A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56878300A 2000-05-10 2000-05-10

Publications (1)

Publication Number Publication Date
SV2002000442A true SV2002000442A (en) 2002-07-03

Family

ID=24272718

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2001000442A SV2002000442A (en) 2000-05-10 2001-05-09 METHOD FOR REGULATING ANGIOGENESIS USING RYK PROTEIN REF. MSB-7266-SV

Country Status (13)

Country Link
EP (1) EP1287121A2 (en)
JP (1) JP2004527206A (en)
AR (1) AR028424A1 (en)
AU (1) AU2001261343A1 (en)
CA (1) CA2408349A1 (en)
CO (1) CO5300464A1 (en)
DO (1) DOP2001000164A (en)
EC (1) ECSP014068A (en)
GT (1) GT200100079A (en)
PE (1) PE20011218A1 (en)
SV (1) SV2002000442A (en)
UY (1) UY26696A1 (en)
WO (1) WO2001085789A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003206854A1 (en) * 2002-02-06 2003-09-02 Developgen Aktiengesellschaft Fur Entwicklungsbiologische Forschung Kinases involved in the regulation of energy homeostasis
JO3283B1 (en) 2011-04-26 2018-09-16 Sanofi Sa Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri)
TR201909951T4 (en) 2014-07-18 2019-07-22 Sanofi Sa A method for predicting the outcome of aflibercept treatment of a patient suspected of having cancer.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2135471A1 (en) * 1992-05-11 1993-11-25 Steven A. Stacker Receptor-type tyrosine kinase-like molecules
AU4606196A (en) * 1994-12-23 1996-07-19 Ludwig Institute For Cancer Research Assay, receptor proteins and ligands
AU4278299A (en) * 1998-06-11 1999-12-30 Astrazeneca Ab Human receptor tyrosine kinase
ES2316194T3 (en) * 1998-10-28 2009-04-01 Cornell Research Foundation, Inc. METHODS FOR THE REGULATION OF ANGIOGENESIS AND VASCULAR INTEGRITY USING THE BDNF, NT-3 AND NT-4 LIGANDS.

Also Published As

Publication number Publication date
DOP2001000164A (en) 2002-05-15
WO2001085789A2 (en) 2001-11-15
CA2408349A1 (en) 2001-11-15
WO2001085789A3 (en) 2002-05-16
ECSP014068A (en) 2002-02-25
JP2004527206A (en) 2004-09-09
UY26696A1 (en) 2001-12-28
AR028424A1 (en) 2003-05-07
EP1287121A2 (en) 2003-03-05
AU2001261343A1 (en) 2001-11-20
PE20011218A1 (en) 2002-02-01
CO5300464A1 (en) 2003-07-31
GT200100079A (en) 2001-12-31

Similar Documents

Publication Publication Date Title
ES2166783T3 (en) ACTIVATED FACTOR VIII USED AS A THERAPEUTIC AGENT AND METHOD FOR THE TREATMENT OF FACTOR DEFICIENCY VIII.
CO4830493A1 (en) ANTIBODIES AGAINST HUMAN CD40
CY1107248T1 (en) SUSPENED PROTEINS
NO962088L (en) Preparation for in vivo production of therapeutic products
ECSP045065A (en) QUERATINOCITS USED AS A BIOLOGICALLY ACTIVE SUBSTANCE IN WOUND TREATMENT
DE60142084D1 (en) USE OF GLP-2 IN CONNECTION WITH ANOTHER THERAPEUTIC AGENT IN BONE DISEASES
ATE365550T1 (en) USE OF A PROTEIN KINASE INHIBITOR SUCH AS GENISTEIN IN THE TREATMENT OF DIABETIC RETINOPATHY
SV2002000442A (en) METHOD FOR REGULATING ANGIOGENESIS USING RYK PROTEIN REF. MSB-7266-SV
DK1343472T3 (en) Thixotropic nasal spray
ES2170390T3 (en) FLUORENONAS ALQUILOXIAMINO-SUBSTITUIDAS AND ITS USE AS INHIBITORS OF THE PROTEIN KINASA-C.
ES2110057T3 (en) MEDICINAL COMPOSITION CONTAINING TCF-II.
DE60107444D1 (en) USE OF A POLLEN EXTRACT CONTAINER FOR THE TREATMENT OF EDEMS
SV2002000362A (en) PROTEINS THAT HAVE AN ANGIOGENESIS MODULATING ACTIVITY REF.MSB-7265-SV
ITTO20000441A0 (en) THERAPEUTIC COMPOSITION FOR THE TREATMENT OF PSORIASIS.
DOP2001000141A (en) PROTEIN ACTING AS AN ANGIOGENIC MODULATOR
ATE374048T1 (en) USE OF MATRIX PROTEIN FOR CONTROLLED TISSUE REGENERATIONS
DE3883044D1 (en) TUMOR FIGHTING ACTIVE SUBSTANCE.
CO5070621A1 (en) METHOD FOR INCREASING THE OSEO VOLUME
SE9904863D0 (en) New use
AR017170A1 (en) OPHTHALMOLOGICAL COMPOSITION
AR023464A1 (en) NEW NOVELS OF THE OX2 PROTEIN OF MAMMER AND RELATED REAGENTS
AR016200A1 (en) THE USE OF A COMPOSITION THAT INCLUDES ONE OR MORE COMPOUNDS CONTAINING SULFUR FOR THE MANUFACTURE OF A MEDICINAL PRODUCT TO INCREASE THE PERMEABILITY OF THE HUMAN CORN FABRIC, AND A KIT THAT INCLUDES SUCH COMPOSITION
FI20030379A0 (en) New pharmaceutical composition
ES2175550T3 (en) PROCEDURE TO INDUCE PROTEINS OF THERAPEUTIC ACTION.
SV1994000023A (en) SUBSTITUTED PYRROLES REF. RAN 4070/90

Legal Events

Date Code Title Description
FD Lapse